Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 1717 Main Street, Suite 3388 DALLAS TX 75201 |
Tel: | N/A |
Website: | https://vaxxinity.com |
IR: | See website |
Key People | ||
Louis Reese Executive Chairman | Mei Mei Hu President, Chief Executive Officer, Co-Founder, Director | Jason Pesile Senior Vice President - Finance and Accounting |
Sumita Ray Chief Legal & Administrative Officer | Farshad Guirakhoo Chief Scientific Officer | Ulo Palm Chief Medical Officer |
Business Overview |
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer's disease (AD) and UB-312, which targets the pathological process of Parkinson's disease (PD) and other so-called synucleinopathies. |
Financial Overview |
For the fiscal year ended 31 December 2023, Vaxxinity Inc revenues was not reported. Net loss decreased 24% to $56.9M. Lower net loss reflects Prophylactic and therapeutic vaccines segment loss decrease of 23% to $58.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.60 to -$0.45. |